Now Available: Spotlight on DELFI Diagnostics CEO Susan Tousi. Click here to read.
DELFI Diagnostics is developing a new generation of liquid biopsies that could advance these applications. Built on a new method called fragmentomics and amplified by machine learning, DELFI’s approach is already showing promise, providing early detection for lung, liver and other cancers, and could provide essential insights to inform precision medicine.
Illumina Ventures, a leading genomics and precision health venture firm, today announced plans to launch Illumina® Ventures Labs.
Alamar Biosciences, a company powering precision proteomics to enable the earliest detection of diseases, and Frazier Life Sciences, announced the launch of Attovia Therapeutics, a newly formed company focused on creating a pipeline of biotherapeutics in immune-mediated disease and cancer.
Led by Illumina Ventures and RA Capital to discover and deploy microbes that will fight climate change. Illumina Ventures’ Charles Lin, PhD, who has joined Pluton’s Board of Directors, expressed his excitement about the fund’s first AgBio investment, “In the past two decades, we have witnessed how genomics revolutionized the landscape of human diagnostics and therapeutics. We expect genomics to...
Your screen does not meet the requirements for generating previews. Adjust your screen width to exactly 1920px before proceeding, otherwise you'll not be able to generate previews.
